Daxor Corporation (DXR)vsMerck & Company Inc (MRK)
DXR
Daxor Corporation
$10.60
-4.39%
HEALTHCARE · Cap: $61.88M
MRK
Merck & Company Inc
$120.79
-1.42%
HEALTHCARE · Cap: $285.64B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 246414295% more annual revenue ($65.77B vs $26,690). DXR leads profitability with a 34359.0% profit margin vs 13.6%. DXR trades at a lower P/E of 6.5x. MRK earns a higher WallStSmart Score of 50/100 (D+).
DXR
Hold45
out of 100
Grade: D+
MRK
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for DXR.
Margin of Safety
-49.3%
Fair Value
$80.88
Current Price
$120.79
$39.91 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Reasonable price relative to book value
Keeps 34359 of every $100 in revenue as profit
Earnings expanding 329.3% YoY
Conservative balance sheet, low leverage
Every $100 of equity generates 23 in profit
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
Weak financial health signals
Revenue declined 82.6%
Negative free cash flow — burning cash
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : DXR
The strongest argument for DXR centers on P/E Ratio, Price/Book, Profit Margin. Profitability is solid with margins at 34359.0% and operating margin at -9661.0%.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : DXR
The primary concerns for DXR are Market Cap, Piotroski F-Score, Revenue Growth.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Key Dynamics to Monitor
DXR profiles as a declining stock while MRK is a value play — different risk/reward profiles.
DXR carries more volatility with a beta of 0.26 — expect wider price swings.
MRK is growing revenue faster at 4.9% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (50/100 vs 45/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Daxor Corporation
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Daxor Corporation, a medical device company, provides cryobank and biotechnology services in the United States. The company is headquartered in New York, New York.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?